search
Back to results

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

Primary Purpose

Pituitary Tumor, Pain

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
IV Caldolor
IV Placebo
Sponsored by
St. Joseph's Hospital and Medical Center, Phoenix
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pituitary Tumor

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patient undergoing ENTS surgery for resection of pituitary tumor.
  • Adults >18 years and <80 years of age.
  • English speaking and literate or able to understand the use of a pain scale.
  • Body Mass Index >19 and <40 kg/m2

Exclusion Criteria:

  • Renal failure (acute or chronic) or creatinine >2.0
  • Allergy or intolerance to acetaminophen, ibuprofen, or opioids
  • Pre-operative opioid tolerance, dependence, or abuse
  • Anaphylaxis to opioids
  • History of peptic ulcer disease or recent gastrointestinal bleed requiring surgery
  • Cirrhosis, hepatitis, liver transplant, or liver function studies out of normal range, defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin> 3x upper limit of normal range
  • Subject unwilling or unable to sign informed consent for the study
  • Pregnancy
  • Incarcerated patients

Sites / Locations

  • St. Joseph's Hospital and Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

IV Caldolor (ibuprofen)

standard treatment group

Arm Description

Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.

IV placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.

Outcomes

Primary Outcome Measures

Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour)
Comparison of pain scores between two arms using Visual Analog Scale (VAS) for Pain. Units of measure are 0=No Pain, 1=Annoying, 2=Mild Pain, 3=Troublesome, 4=Nagging Pain, Uncomfortable, 5=Distressing, 6=Miserable, 7=Horrible, 8=Intense, Dreadful, 9=Unbearable, 10=Worst Possible Pain. Higher values represent a worse outcome. There are no subscales.

Secondary Outcome Measures

Breakthrough Narcotic Requirement
Rescue narcotic in both groups will be recorded and compared using a standard equianalgesic oral morphine equivalent (OME) calculation
Other Adverse Events
Epistaxis, potentially related to IV ibuprofen, will be compared between two groups

Full Information

First Posted
January 14, 2015
Last Updated
October 5, 2021
Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
search

1. Study Identification

Unique Protocol Identification Number
NCT02351700
Brief Title
Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
Official Title
Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
February 1, 2015 (Actual)
Primary Completion Date
March 1, 2016 (Actual)
Study Completion Date
April 1, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Joseph's Hospital and Medical Center, Phoenix

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized, double-blind, placebo-controlled intervention trial involving 100 treated subjects undergoing endonasal trans-sphenoidal (ENTS) resection of pituitary lesion. Subjects will be randomized into two groups: 50 treated in the opioid-sparing arm and 50 treated in the standard post-operative medication arm.
Detailed Description
Post-operative pain control is a common concern patients have when they consider undergoing a surgical procedure. Although effective for treating acute pain, opioid analgesics are also associated with dose-dependent adverse effects, including constipation, nausea and vomiting, altered mental status, and respiratory depression, all of which have been shown to increase patient length of stay. The use of non-opioid analgesics with different mechanisms of actions for acute pain control via a multi-modal approach is efficacious in reducing opioid consumption, decreasing the incidence of adverse effects, improving patient satisfaction and recovery time, and decreasing hospital costs.Certain minimally invasive procedures may afford many patients the opportunity to achieve adequate post-operative pain control with minimal to no requirement of opioid analgesics, thereby sparing the patient known adverse effects that can increase length of stay and costs. The ENTS approach for resection of pituitary tumors is the standard surgical procedure for these lesions, and is associated with pain that is more easily managed post-operatively, making it an ideal procedure for an opioid-sparing post-operative pain regimen. Anecdotally, the investigators note that in the investigator's post-operative pituitary patient population that post-operative pain can frequently be adequately managed with scheduled non-opioid analgesics, often without requiring breakthrough opioid doses. Another safe and effective non-opioid analgesic that is widely used in multi-modal pain management for moderate pain is IV Caldolor (ibuprofen). After literature review, the investigators were unable to find a study that had attempted to use an opioid-sparing analgesic regimen for post-operative pain control following ENTS approach for resection of pituitary tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pituitary Tumor, Pain

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IV Caldolor (ibuprofen)
Arm Type
Active Comparator
Arm Description
Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
Arm Title
standard treatment group
Arm Type
Placebo Comparator
Arm Description
IV placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
Intervention Type
Drug
Intervention Name(s)
IV Caldolor
Other Intervention Name(s)
IV ibuprofen, Opioid Sparing group
Intervention Description
IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
Intervention Type
Drug
Intervention Name(s)
IV Placebo
Other Intervention Name(s)
Standard treatment group
Intervention Description
IV Placebo intraoperatively and postoperatively
Primary Outcome Measure Information:
Title
Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour)
Description
Comparison of pain scores between two arms using Visual Analog Scale (VAS) for Pain. Units of measure are 0=No Pain, 1=Annoying, 2=Mild Pain, 3=Troublesome, 4=Nagging Pain, Uncomfortable, 5=Distressing, 6=Miserable, 7=Horrible, 8=Intense, Dreadful, 9=Unbearable, 10=Worst Possible Pain. Higher values represent a worse outcome. There are no subscales.
Time Frame
mean pain score over 48 hours
Secondary Outcome Measure Information:
Title
Breakthrough Narcotic Requirement
Description
Rescue narcotic in both groups will be recorded and compared using a standard equianalgesic oral morphine equivalent (OME) calculation
Time Frame
until discharge from hospital, an expected stay of 2 days
Title
Other Adverse Events
Description
Epistaxis, potentially related to IV ibuprofen, will be compared between two groups
Time Frame
until discharge from hospital, an expected stay of 2 days
Other Pre-specified Outcome Measures:
Title
Total Cost of Hospital Charges Compared Between Two Arms
Description
Total hospital costs for patients in IV ibuprofen arm compared to IV placebo arm
Time Frame
until discharge from hospital, an expected stay of 2 days
Title
The Number of Participants Who Have a Bowel Movement During Hospitalization in Both Groups
Description
patients with one or more bowel movement(s) in the first 48 hours after surgery
Time Frame
until discharge from hospital, an expected stay of 2 days
Title
Length of Stay in Hospital Compared Between Two Arms
Description
Length of hospital stay from time of surgery to time of discharge.
Time Frame
until discharge from hospital, an expected stay of 2 days
Title
Total Number of Doses of Any Anti-emetic Required Post-operatively in Both Groups
Description
Use of antiemetics in first 48 hours after surgery
Time Frame
until discharge from hospital, an expected stay of 2 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patient undergoing ENTS surgery for resection of pituitary tumor. Adults >18 years and <80 years of age. English speaking and literate or able to understand the use of a pain scale. Body Mass Index >19 and <40 kg/m2 Exclusion Criteria: Renal failure (acute or chronic) or creatinine >2.0 Allergy or intolerance to acetaminophen, ibuprofen, or opioids Pre-operative opioid tolerance, dependence, or abuse Anaphylaxis to opioids History of peptic ulcer disease or recent gastrointestinal bleed requiring surgery Cirrhosis, hepatitis, liver transplant, or liver function studies out of normal range, defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin> 3x upper limit of normal range Subject unwilling or unable to sign informed consent for the study Pregnancy Incarcerated patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew S Little, MD
Organizational Affiliation
Barrow Neurosurgical Associates physician with SJHMC privileges
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Joseph's Hospital and Medical Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22570188
Citation
Pizzi LT, Toner R, Foley K, Thomson E, Chow W, Kim M, Couto J, Royo M, Viscusi E. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy. 2012 Jun;32(6):502-14. doi: 10.1002/j.1875-9114.2012.01101.x. Epub 2012 May 8.
Results Reference
background
PubMed Identifier
23205862
Citation
Husted H. Fast-track hip and knee arthroplasty: clinical and organizational aspects. Acta Orthop Suppl. 2012 Oct;83(346):1-39. doi: 10.3109/17453674.2012.700593.
Results Reference
background
PubMed Identifier
21255528
Citation
Costantini R, Affaitati G, Fabrizio A, Giamberardino MA. Controlling pain in the post-operative setting. Int J Clin Pharmacol Ther. 2011 Feb;49(2):116-27. doi: 10.5414/cp201401.
Results Reference
background
PubMed Identifier
10713196
Citation
Badie B, Nguyen P, Preston JK. Endoscopic-guided direct endonasal approach for pituitary surgery. Surg Neurol. 2000 Feb;53(2):168-72; discussion 172-3. doi: 10.1016/s0090-3019(99)00195-0.
Results Reference
background
PubMed Identifier
15248627
Citation
Dahl V, Dybvik T, Steen T, Aune AK, Rosenlund EK, Raeder JC. Ibuprofen vs. acetaminophen vs. ibuprofen and acetaminophen after arthroscopically assisted anterior cruciate ligament reconstruction. Eur J Anaesthesiol. 2004 Jun;21(6):471-5. doi: 10.1017/s026502150400609x.
Results Reference
background
PubMed Identifier
19843482
Citation
Southworth S, Peters J, Rock A, Pavliv L. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain. Clin Ther. 2009 Sep;31(9):1922-35. doi: 10.1016/j.clinthera.2009.08.026.
Results Reference
background
PubMed Identifier
20609131
Citation
Singla N, Rock A, Pavliv L. A multi-center, randomized, double-blind placebo-controlled trial of intravenous-ibuprofen (IV-ibuprofen) for treatment of pain in post-operative orthopedic adult patients. Pain Med. 2010 Aug;11(8):1284-93. doi: 10.1111/j.1526-4637.2010.00896.x. Epub 2010 Jun 30.
Results Reference
background
PubMed Identifier
20642488
Citation
Kroll PB, Meadows L, Rock A, Pavliv L. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (i.v.-ibuprofen) in the management of postoperative pain following abdominal hysterectomy. Pain Pract. 2011 Jan-Feb;11(1):23-32. doi: 10.1111/j.1533-2500.2010.00402.x.
Results Reference
background
PubMed Identifier
24400921
Citation
Chung KC, Barlev A, Braun AH, Qian Y, Zagari M. Assessing analgesic use in patients with advanced cancer: development of a new scale--the Analgesic Quantification Algorithm. Pain Med. 2014 Feb;15(2):225-32. doi: 10.1111/pme.12299. Epub 2014 Jan 8.
Results Reference
background
PubMed Identifier
28298041
Citation
Shepherd DM, Jahnke H, White WL, Little AS. Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery. J Neurosurg. 2018 Feb;128(2):444-451. doi: 10.3171/2016.10.JNS161355. Epub 2017 Mar 3.
Results Reference
result

Learn more about this trial

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

We'll reach out to this number within 24 hrs